Comparison of Oncostatin M in Patients with Chronic Periodontitis with and without Diabetes


  • Amulya Kolluri
  • Pratibha Gopalkrishna
  • Venkat Rao Josyula
  • Aditya Kiran Gatta
  • Kalyana Pentapati Chakravarthy


Diabetes Mellitus, Periodontitis, Gingiva, Inflammation, Cytokines


Objective: To compare the Oncostatin M (OSM) concentrations in tissues of patients with chronic periodontitis with and without diabetes. Material and Methods: Sixty-four subjects visiting the dental outpatient department were categorized as “healthy” (Group 1), “periodontitis” (Group 2), and “diabetes with periodontitis” (Group 3) groups. The clinical oral examination included assessment of plaque, gingivitis, probing depth, clinical attachment level. Blood glucose was assessed for group 3 patients. OSM concentration in the tissues was assessed using ELISA in all groups. Results: The mean OSM was 0.02 ± 0.04 pg/mg in the healthy group, 0.12 ± 0.09 pg/mg in the chronic periodontitis group and 0.13 ± 0.10 pg/mg in the diabetes-periodontitis group. A significantly higher mean OSM was seen in Group 2 and Group 3 than Group 1. The amount of OSM positively correlated with probing depth and clinical attachment level. Conclusion: Periodontal disease causes a rise in Oncostatin M, independent of the diabetic status. Expression of OSM in the gingival tissues can serve as an inflammatory marker.


Verhulst MJL, Loos BG, Gerdes VEA, Teeuw WJ. Evaluating all potential oral complications of diabetes mellitus. Front Endocrinol 2019; 10:56.

Lalla E, Lamster IB, Drury S, Fu C, Schmidt AM. Hyperglycemia, glycoxidation and receptor for advanced glycation endproducts: Potential mechanisms underlying diabetic complications, including diabetes-associated periodontitis. Periodontol 2000 2000; 23:50-62.

Perraudin JP. The biochemical aspects of diabetes in oral health. Br J Diabetes 2019; 19(2):93-8.

Houben E, Hellings N, Broux B. Oncostatin M: an underestimated player in the central nervous system. Front Immunol 2019; 10:1165.

Goyden J, Tawara K, Hedeen D, Willey JS, Oxford JT, Jorcyk CL. The effect of OSM on MC3T3-E1 osteoblastic cells in simulated microgravity with radiation. PLoS One 2015; 10(6):e0127230.

Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA, et al. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 1997; 100(1):158-68.

Garcia JP, Utomo L, Rudnik-Jansen I, Du J, Zuithoff NPA, Krouwels A, et al. Association between Oncostatin M expression and inflammatory phenotype in experimental arthritis models and osteoarthritis patients. Cells 2021; 10(3):508.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017; 23(5):579-89.

Stawski L, Trojanowska M. Oncostatin M and its role in fibrosis. Connect Tissue Res 2019; 60(1):40-9.

Akarsu M, Hurşitoğlu M, Toprak Z, Yoldemir ŞA, Altun Ö, Toprak ID, et al. Relationships among oncostatin M, insulin resistance, and chronic inflammation: a pilot study. Arch Endocrinol Metab 2019; 64(1):38-44.

Pradeep AR, Thorat Manojkumar S, Garima G, Raju A. Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. Biomarkers 2010; 15(3):277-82.

Thorat M, AR P, Garg G. Correlation of levels of Oncostatin M cytokine in crevicular fluid and serum in periodontal disease. Int J Oral Sci 2010; 2(4):198-207.

Khan F, Rathod S, Kolte A, Gupta M, Chari S, Gonde N. Quantitative analysis of oncostatin M levels in chronic periodontitis patients. J Int Clin Dent Res Organ 2020; 12(1):33-37.

Jones MM, Vanyo ST, Ibraheem W, Maddi A, Visser MB. Treponema denticola stimulates Oncostatin M cytokine release and de novo synthesis in neutrophils and macrophages. J Leukoc Biol 2020; 108(5):1527-41.

Löe H, Silness J. Periodontal disease in pregnancy I. Prevalence and severity. Acta Odontol Scand 1963; 21:533-51.

Silness J, Löe H. Periodontal disease in pregnancy II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964; 22:121-35.

Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. Oncostatin M synergistically induces CXCL10 and ICAM-1 expression in IL-1β-stimulated-human gingival fibroblasts. J Cell Biochem 2010; 111(1):40-8.

Lin SJ, Chen YL, Kuo MY Bin, Li CL, Lu HK. Measurement of gp130 cytokines - Oncostatin M and IL-6 in gingival crevicular fluid of patients with chronic periodontitis. Cytokine 2005; 30(4):160-7.

Lu H-K, Chen Y-L, Chang H-C, Li C-L, Kuo MYP. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 2006; 41(4):354-60.

Zhou L, Bi C, Gao L, An Y, Chen F, Chen F. Macrophage polarization in human gingival tissue in response to periodontal disease. Oral Dis 2019; 25(1):265-73.

Hanes PJ, Krishna R. Characteristics of inflammation common to both diabetes and periodontitis: are predictive diagnosis and targeted preventive measures possible? EPMA J 2010; 1(1):101-16.




How to Cite

Kolluri, A. ., Gopalkrishna, P. ., Josyula, V. R. ., Gatta, A. K. ., & Chakravarthy, K. P. . (2022). Comparison of Oncostatin M in Patients with Chronic Periodontitis with and without Diabetes. Pesquisa Brasileira Em Odontopediatria E Clínica Integrada, 22, e210136. Retrieved from



Original Articles